Increased Usage of Carbapenems, Pfizer’s Tygacil and Colistin for Gram-Negative Infections Represents Shifts in Treatment to Later-Lines of Therapies and to Reserved Antibiotics in Both U.S. and European Markets BioTrends Research Group and Arlington Medical Resources Release TreatmentTrends®: Gram-Negative Infections (EU) Report Business Wire EXTON, Pa. -- June 13, 2012 BioTrends Research Group and Arlington Medical Resources (AMR) in their TreatmentTrends: Gram-Negative Infections (EU) report find that drug-resistant and multi-drug resistant (MDR) Gram-negative (GN) pathogens, including extended spectrum beta lactamase-producing pathogens, MDR Pseudomonas aeruginosa and Acinetobacter species are on the rise in Europe. Moreover, the study finds that the lack of effective treatment options for these infections is driving increased prescribing of colistin, Pfizer’s Tygacil and carbapenems, namely AstraZeneca’s Merrem (meropenem, generics), Merck’s Primaxin (imipenem-cilastatin, generics) and Janssen’s Doribax (doripenem). In fact, nearly 80 percent of surveyed physicians report increasing their usage of colistin for Gram-negative infections (GNIs) and approximately half of Tygacil users indicate prescribing more Tygacil for the treatment of complicated intra-abdominal infections due to GN pathogens. Approximately, one-third of infectious diseases specialists and one-fifth of critical care/intensive care unit (ICU) specialists cite increased usage of the carbapenems as the major treatment change for the management of GNIs in the past five years. “The rising rates of drug-resistance in GNIs in both the United States and Europe and the uptake of drugs in the inpatient setting with noted safety risks emphasizes the need for new therapies with efficacy in difficult-to-treat GNIs, such as hospital-acquired pneumonia, and have a high barrier to resistance development,” said Associate Therapeutic Class Director of Infectious Diseases Brenda Perez-Cheeks, Ph.D. For the management of P. aeruginosa infections, a majority of surveyed physicians in Europe report prescribing a combination of two anti-pseudomonal antibiotics with a preference for using an aminoglycoside as part of a combination regimen. This is in contrast to BioTrends and AMR’s findings in TreatmentTrends: Gram-Negative Infections (US), where combinations of two beta-lactam antibiotics or a beta-lactam and a fluoroquinolone are the leading therapies prescribed by U.S. physicians. Physician perceptions of the carbapenems for the management of GNIs are highly favorable and European physicians rate meropenem highest on performance in GNIs as compared to other GN therapies. Although physicians are satisfied with Doribax’s performance in GNIs, only 13 percent of surveyed physicians report prescribing the drug in the past year. With regard to awareness of therapies in development for the treatment of GNIs, ID specialists report the greatest awareness with Basilea’s ceftobiprole, whereas critical care/ICU specialists are most familiar with Intercell’s P. aeruginosa vaccine candidate. Physicians cite a higher degree of awareness of Cubist/Astellas’s CXA-201 and of Forest/AstraZeneca’s CEF-104 and CAZ-AVI versus other GNI products in the pipeline. About TreatmentTrends TreatmentTrends: Gram-Negative Infections (EU) is an annual report that provides insight into the treatment of patients with Gram-negative infections in the hospital setting. Research with 251 infectious diseases specialists and critical care/ICU specialists analyzes the usage and uptake of antibiotics for the treatment of key infections due to emerging and clinically important Gram-negative pathogens in the EU5 markets. TreatmentTrends is a syndicated report series that provides longitudinal information on market dynamics, including insight into practice patterns, attitudes and perceptions, unmet needs, and projected and current use of antibiotics in the hospital. TreatmentTrends: Gram-Negative Infections (US), the companion study, tracking the usage of antibiotics in the U.S. to treat these infections, was published on April 2012. About BioTrends Research Group BioTrends Research Group provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 321-9400 or www.bio-trends.com. BioTrends is a Decision Resources Group company. About Arlington Medical Resources AMR (www.AMR-data.com) serves the market intelligence needs of the pharmaceutical and diagnostic imaging industries. Research includes clinical inpatient databases that directly link anti-infective drugs with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits. AMR is a Decision Resources Group company. About Decision Resources Group Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group atwww.DecisionResourcesGroup.com. All company, brand, or product names contained in this document may be trademarks of their respective holders. Contact: BioTrends Research Group, LLC Brenda Perez-Cheeks, Ph.D., 610-908-7255 email@example.com or Decision Resources Group Lisa Osgood, 781-993-2606 firstname.lastname@example.org
Increased Usage of Carbapenems, Pfizer’s Tygacil and Colistin for Gram-Negative Infections Represents Shifts in Treatment to
Press spacebar to pause and continue. Press esc to stop.